JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 88.0%

Neg 88% Neu 0% Pos 0%

JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.